Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review

Goyal, Madhusudan; Tewatia, Nisha; Vashisht, Hemlata; Jain, Reena; Kumar, Satish

doi:10.1016/j.jiph.2021.04.011

Cited by 19 publications

(18 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) represents the most pressing and challenging threat to the present global public health and economy (1)(2)(3). At the time of writing this manuscript (04 November 2021), 247,968,227 confirmed cases of COVID-19, including 5,020,204 deaths, had been reported worldwide by the World Health Organization (WHO) (4).…”

Section: Introductionmentioning

confidence: 99%

Identification of SARS-CoV-2 Variants and Their Clinical Significance in Hefei, China

Cheng

Zhang

et al. 2022

Front. Med.

View full text Add to dashboard Cite

The ongoing coronavirus disease 2019 (COVID-19) pandemic represents one of the most exigent threats of our lifetime to global public health and economy. As part of the pandemic, from January 10 to March 10, 2020, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) began to spread in Hefei (Anhui Province, China) with a total of 174 confirmed cases of COVID-19. During this period, we were able to gather critical information on the transmission and evolution of pathogens through genomic surveillance. Particularly, the objective of our study was to track putative variants of SARS-CoV-2 circulating in Hefei for the first time and contribute to the global effort toward elucidating the molecular epidemic profile of the virus. Patients who showed symptoms of COVID-19 were routinely tested for SARS-CoV-2 infections via RT-PCR at the First Affiliated Hospital of Anhui Medical University. Whole-genome sequencing was performed on 97 clinical samples collected from 29 confirmed COVID-19 patients. As a result, we identified a local novel single-nucleotide polymorphism site (10,380) harboring a G → T mutation (Gly → Val) in Hefei. Further phylogenetic network analysis with all the sequences of SARS-CoV-2 deposited in GenBank collected in East and Southeast Asia revealed a local subtype of S-type SARS-CoV-2 (a1) harboring a C → T synonymous mutation (Leu) at position 18,060 of ORF1b, likely representing a local SARS-CoV-2 mutation site that is obviously concentrated in Hefei and the Yangtze River Delta region. Moreover, clinical investigation on the inflammatory cytokine profile of the patients suggested that mutations at positions 18,060 (the shared variable site of subtype a1) and 28,253(harboring a C → T synonymous mutation, Phe) were associated with milder immune responses in the patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of SARS-CoV-2 Variants and Their Clinical Significance in Hefei, China

Cheng

Zhang

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Viruses are pernicious because they can spread and infect their targets rapidly [ 1 ]. Many dangerous viruses have their own RNA genomes that readily mutate [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Dual-site ligation-assisted loop-mediated isothermal amplification (dLig-LAMP) for colorimetric and point-of-care determination of real SARS-CoV-2

2022

View full text Add to dashboard Cite

A probing system has been developed based on dual-site ligation-assisted loop-mediated isothermal amplification (dLig-LAMP) for the selective colorimetric detection of SARS-CoV-2. This approach can induce false-positive and -negative detection in real clinical samples; dLig-LAMP operates with improved selectivity. Unlike RT-LAMP, the selectivity of dLig-LAMP is determined in both the ligation and primer binding steps, not in the reverse transcription step. With this selective system in hand, we developed a colorimetric signaling system for point-of-care detection. We also developed a colorimetric probe for sensing pyrophosphate, which arises as a side product during the LAMP DNA amplification. Thus, dLig-LAMP appears to be an alternative method for improving the selectivity problems associated with reverse transcription. In addition, combining dLig-LAMP with colorimetric pyrophosphate probing allows point-of-care detection of SARS-CoV-2 within 1 h with high selectivity. Graphical abstract Supplementary Information The online version contains supplementary material available at 10.1007/s00604-022-05293-7.

show abstract

“…Casirivimab and Imdevimab are mainly human immunoglobulin G-1 (IgG1). Figure 9 describes a method of production of monoclonal antibodies (Richardson et al 2020;Ceribelli et al 2020;Marovich et al 2020;Zost et al 2020;Goyal et al 2021;Yang et al 2020;Clinical Trial Arena 2020;Phan et al 2021).…”

Section: Upper Respiratorymentioning

confidence: 99%

“…Recently in the repurposing of drugs also includes it for further research on possible treatments of coronavirus disease. Bemcentinib (AXL kinase suppressor) prevents entry of virus to the cell as well as also inhibits type 1 interferon, supporting its use in SARS-CoV-2 Goyal et al ( 2021 ) Bevacizumab The brand name of the drug is Avastin prescribed for cancer treatment also repurposed in search of possible covid-19 treatment prescribed for 20 patients in China (Shandong University, Jinan, Qilu hospital). Currently in the second and third phases of clinical trials.…”

Section: Introductionmentioning

confidence: 99%

Current trends in diagnosis and treatment strategies of COVID-19 infection

Tiwari¹,

Kumar

Tiwari³

et al. 2021

Environ Sci Pollut Res

View full text Add to dashboard Cite

Coronaviruses are terrifically precise and adapted towards specialized respiratory epithelial cells, observed in organ culture and human volunteers both. This virus is found to possess an unpredictable anti-viral T-cell response which in turn results in T-cell activation and finally apoptosis, leading to cytokine storm and collapse of the whole immune system. The present review provides comprehensive information regarding SARS-CoV-2 infection, mutant strains, and the impact of SARS-COV-2 on vital organs, the pathophysiology of the disease, diagnostic tests available, and possible treatments. It also includes all the vaccines developed so far throughout the world to control this pandemic. Until now, 18 vaccines have been approved by the WHO and further 22 vaccines are in the third trial. This study also provides up-to-date information regarding the drugs repurposed in clinical trials and the recent status of allopathic drugs along with its result. Although vaccines are available, specific treatment is not available for the disease. Furthermore, the effect of vaccines on new variants is a new area of research at this time. Therefore, a preventive attitude is the best approach to fight against this virus.

show abstract

Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review

Cited by 19 publications

References 108 publications

Identification of SARS-CoV-2 Variants and Their Clinical Significance in Hefei, China

Identification of SARS-CoV-2 Variants and Their Clinical Significance in Hefei, China

Dual-site ligation-assisted loop-mediated isothermal amplification (dLig-LAMP) for colorimetric and point-of-care determination of real SARS-CoV-2

Current trends in diagnosis and treatment strategies of COVID-19 infection

Contact Info

Product

Resources

About